Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids

NCT00589823 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancers, Pain

Interventions

DRUG: Fentanyl citrate
DRUG: Immediate release morphine sulphate

Sponsor

Archimedes Development Ltd